Indications
- Symptomatic Bradycardia (see Bradycardia, [[Bradycardia]])
- Hypotension (see Hypotension, [[Hypotension]])
Pharmacology
- α1-Adrenergic Receptor Agonist (see α1-Adrenergic Receptor Agonists, [[α1-Adrenergic Receptor Agonists]])
- β1-Adrenergic Receptor Agonist
- β2-Adrenergic Receptor Agonist (see β2-Adrenergic Receptor Agonists, [[β2-Adrenergic Receptor Agonists]])
-
Dopamine Receptor Agonist (see Dopamine Receptor Agonists, [[Dopamine Receptor Agonists]])
-
Actions on Pulmonary Vascular Tone
Administration
- IV (Bradycardia, Hypotension):
Adverse Effects
Cardiovascular Adverse Effects
- QT Prolongation without Definite Association with Torsade (see Torsade, [[Torsade]])
- Sinus Tachycardia (see Sinus Tachycardia, [[Sinus Tachycardia]])
Pulmonary Adverse Effects
- Direct Action on Pulmonary Vascular Tone: exacerbating hypoxemia (particularly in ALI/ARDS)
- Suppression of Hypercapnic Response: may exacerbate hypoventilation (and exacerbate hypoxemia, particularly in ALI/ARDS)
Other Adverse Effects
- xxx
References
- xxx